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Background: Acute pancreatitis is a life-threatening necroinflammatory disease that is characterized by systemic
inflammatory response syndrome and acute lung injury even in its very first days. Erythropoietin (EPO) is a hormone
considered as an antiapoptotic and cytoprotective with observed receptors of anti-inflammatory effect on organs
apart from the liver and the kidneys. In this study, the effects of EPO on pulmonary mast cells and on secondary
injury caused by acute pancreatitis are investigated.
Methods: Twenty one Wistar Albino rats were divided into three groups—sham, control, and EPO groups—with 7
rats per group. Pancreatitis was induced by administering 4.5% sodium taurocholate into the pancreatic duct. A
1000 U/kg/day dosage (three times) of EPO was administered to the EPO group. Blood urea nitrogen (BUN),
creatinine, amylase, and troponin I in the serum were studied; and lung, kidney, brain, and heart tissues were
examined histopathologically.
Results: There were no histopathological changes in the other organ tissues except for the lung tissue. Compared
to the control group, the EPO group showed significantly reduced alveolar hemorrhage, septal neutrophil
infiltration, lung wall thickness score, and mast cell count in the lung tissue.
Conclusions: Administration of EPO reduces the mast cell count and lung wall thickness, and it reduces the
alveolar hemorrhage and septal infiltration induced by acute pancreatitis.
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Acute pancreatitis (AP) is a life-threatening necroinflam-
matory disease. Systemic inflammatory response syndrome
(SIRS) that develops during the course of the disease and
owing to multiple organ failure (MOF) is a major cause of
morbidity and mortality. A large number of patients lose
their lives due to acute lung injury (ALI) and acute re-
spiratory distress syndrome (ARDS) [1]. The disease con-
fines itself to a single organ 80% of the time; however,
with the development of MOF, it is related to mortality by
40% [2,3]. Although supporting therapies have been deve-
loped for the treatment of pancreatitis, definite treatments
capable of reducing the severeness of the inflammation do
not yet exist [4].
The erythropoietin (EPO) gene is located on chromo-
some 7 and encodes a polypeptide chain containing 193* Correspondence: tanzerkorkmaz@gmail.com
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reproduction in any medium, provided the oramino acids. The circulatory mature protein is a 30.4-
kDa glycoprotein that has a span of 165 amino acids [5].
EPO is a hormone mainly produced in the kidneys that
is effective in maintaining the erythrocyte mass in circu-
lation. Furthermore, recent studies have shown that in
addition to the liver and the kidneys, EPO and its recep-
tors are also present in organs such as the heart and the
brain [5]. By its receptors, EPO, as a cytokine has anti-
apoptotic and cytoprotective effects [5-7].
Although mast cells are present in all body tissues,
they are mostly observed around the capillaries of the skin
and the respiratory system and the vessels of the lymphatic
system [8,9]. It has been reported that mast cells play a role
in inflammatory and allergic diseases of the respiratory
system [10-12]. In ischemic injuries, ALI fundamentally
develops through the release of mast-cell-activated cyto-
kines such as histamine and tryptase [12,13]. It is also
reported that mast cells increase inflammation within
seconds in lung tissue through these cytokines [9,13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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logical effects of EPO administration on the tissue in
distant organ damage induced by AP and variations in
the mast cell count.
Methods
This study was approved by the ethics committee of Abant
İzzet Baysal University (No. 375/2012). Twenty-one healthy
male Wistar Albino rats (weight: 150–200 g) were housed
in a climate-controlled facility and given ad libitum access
to food and water.
Experimental groups
21 rats were randomly separated into three groups—sham,
control, and EPO (with induced AP and application of EPO)
groups—with 7 rats per group. After the inducement
of pancreatitis, a dosage of 1000 U/kg/day (5 IU) of in-
traperitoneal EPO (Eprex, 2000 U/0.5 mL from Gürel
İlaç Ticaret, İstanbul) was administered for three days to
the EPO Group.
Study Protocol
All interventions for rats were performed by the same team.
In a temperature-controlled room, anesthesia was induced
by intramuscular injection of a combination of xylazine
hydrochloride (10 mg/kg, Rompun, Bayer, Toronto, Canada)
and ketamine hydrochloride (50 mg/kg), Ketalar, Parke
Davis-Eczacıbaşı, İstanbul, Turkey). The rats were fixed in a
supine position and secured in the dissection tray. Their skin
was shaved with povidone-iodine solution and prepared for
aseptic surgery. The intestinal region was accessed by means
of midline laparotomy, and the duodenum was pulled
downward and laterally. The pancreatic duct was exposed
and entered transduodenally using a 26G catheter. The
sham group was administered 0.2 cc serum physiologic
through the pancreatic duct, and the control as well as the
EPO groups were administered a solution of 0.2 cc serum
physiologic dissolved in 4.5% sodium taurocholate (NaTC)
((Sigma-Aldrich, St. Louis, MO, USA) through slow infusion
into the pancreatic duct [14]. The transduodenal bile duct
and anterior abdominal walls were closed with 6/0 prolen
and 3/0 silk suture, respectively. After the procedure, the
EPO group was administered 1000 U/kg EPO intraperitone-
ally at intervals of 1, 24, and 48 h, and the sham and control
groups were administered the same volume of serum
physiologic intraperitoneally. At the end of the third day,
after sedation, all subjects were sacrificed by exsanguination,
and the heart, kidney, brain, and pulmonary segments were
removed. The blood, blood urea nitrogen (BUN), creatinine,
amylase, and troponin I were examined.
Biological examination
After the procedure, biochemical analyses were performed
on blood samples taken from the abdominal aorta. BUN,creatinine, and amylase tests were performed using COBAS
Integra 800 autoanalyzer (Roche Diagnostics GmbH,
D-68298 Mannheim, Germany); and troponin I tests were
performed using Mini Vidas analyzer (Biomerieux). Ana-
lyses for BUN were performed via the kinetic method using
urease and glutamate dehydrogenase; those for amylase
were performed via the calorimetric enzymatic method, and
those for troponin I were conducted via the enzyme-linked
fluorescent immunoassay method.
Histopathological evaluation
Lung, brain, heart, and kidney tissues taken from the
subjects were fixed in 10% neutral formalin. Sample tis-
sues were submerged in paraffin after being put through
degreed alcohol and xylene. 5-μm-thick sections were
taken and dyed with hematoxylin eosin and toluidine
blue for general examination and for obtaining the mast
cell count, respectively; and they were assessed using a BH2
Olympus light microscope. Histopathological evaluations
were performed on each subject’s lung, brain, heart, and
kidney sample sections. Changes in the lung tissue were
scored in terms of alveolar edema, hemorrhage, cell infiltra-
tion, and alveolar wall thickness. Scoring was assigned as
normal structure (0), minor changes (1), moderate changes
(2), and widespread changes (3) [15]. In the lung tissue of
all subjects, the mast cell count was obtained at 40× scope
magnification in 6 different areas. Histopathological scoring
was performed by a researcher who was not informed
about the subject groups.
Statistical analysis
The SPSS software package (SPSS version 17 for Windows)
was used for statistical analyses. The values were presented
as mean ± standard deviation (SD), which is the normal
distribution of the data, and as median ± standard error
(SE), which is not the normal distribution of data. For
comparison among the groups, Kruskal-Wallis variance
analysis, and for binary analysis, Mann-Whitney test with
Bonferroni correction, were used. These differences were
considered significant when probability was less than 0.05.
Results
All subjects survived during the study process. Biochemical
analysis revealed higher values of amylase in the control
(2747 ∓ 1288,8) than in the other groups (group S:2182 ∓ 0,
group EPO:1931 ∓ 420,4). The troponin I value was
found to be <0.001 ng/mL in all rats in the sham
group, <0.001 mg/dL in four rats and 0.5–22.97 ng/dL
in five rats in the Control group, <0.001 ng/dL in two
rats and 0.2–0.9 ng/dL in all the remaining rats in the
EPO group. The intergroup analyses showed no signifi-
cant variations for amylase, BUN, and troponin I values
but a statistically significant difference for the creatinine
value (p = 0.001) was. Binary comparisons showed that the
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(Median ∓ SE: 0,3 ∓ 01) and the EPO groups (Median ∓ SE:
0,2 ∓ 0,005) (p = 0.001).
Histopathological results
No structural changes were observed in histopathological
examinations of tissue samples taken from the kidney, brain,
and heart but the lung. In the lung, parenchyma of control
group subjects, capillary saturation and hemorrhage, inflam-
matory cell infiltration with accumulation of neutrophils,
lymphocyte cell concentration around vessels, thickening of
interalveolar walls, and fluid within some alveoli were iden-
tified (Figure 1a,b,c,d). Histological changes in the control
and sham groups were also shown in Figure 2.
It was observed that in the subjects of the Control
Group there were mast cells with spread granules in
some areas; and in these areas edema was very significant
(Figure 3a,b). In the EPO group, in addition to the
mast cell count surrounding the vessels, hemorrhage
and edema were observed to be reduced (Figure 3c).
And the presence of scant amount of mast cells in sham
group was shown in Figure 3d.
The scoring used in the histopathological assessment
and the observed histopathological changes including
alveolar congestion, hemorrhage, alveolar septal infiltra-
tion, and alveolar wall thickness are presented in Table 1
and Figures 1 and 3. There was no statistically significant
difference in terms of alveolar congestion (p = 0.368) in
between-groups comparison. When hemorrhage, alveolar
septal infiltration, and alveolar wall thickness scores were
evaluated, a meaningful intergroup difference was found. In
further analysis, a meaningful difference was found betweenFigure 1 Histologic changes in the control group: (a) Extensive hemo
infiltration, (c) vascular proximity lymphocyte infiltration, (d) alveolarthe sham and the control groups, the sham and the EPO
groups, also the control and EPO groups (p = 0.001, 0.002,
and 0.019, respectively) in terms of hemorrhage. A similarly
significant difference was observed in terms of both the
alveolar septal infiltration and the alveolar wall thickness
between the sham and the control groups in addition to
the sham and the EPO groups (p = 0.001 in both cases).
The median count of mast cells in lung tissue samples
was determined as 8 ± 0.5 in the sham group (95% CI,
7.1–9.7), 12 ± 0.8 in the control group (95% CI, 10.5–14.8),
and 9 ± 0.3 in the EPO group (95% CI, 8.2–9.7). In the
control group, pronounced edema and a large number of
mast cells with spread granules surrounding the vessels
were observed (Figure 3a,b). On the other hand, in the
EPO group, in addition to the mast cell count surround-
ing the vessels, hemorrhage and edema were reduced
(Figure 3c). In terms of mast cell count, a significantly
difference was found (p = 0.001) between the groups.
Further analyses showed that this difference was due to
the Control and the EPO groups (p = 0.002). The mast
cell count was observed to be significantly lower in the
EPO group compared to the control group.
Discussion
Although AP is an organ disease, it can cause systemic
diseases in other organs such as the lungs, heart, kidneys,
and brain as well. In published case presentations, acute
myocardial infarction has been identified in patients with
AP. In these patients, despite the ST-T changes in ECG,
enzyme variations, troponin I values, and post-angiography
coronary arteries are found to be normal. It is attributed to
the direct effect of proteolytic enzyme concentrations,rrhage in lung parenchyma, (b) inflammatory cells neutrophil
fluid (hematoxylin eosin-x40).
Figure 2 Histologic changes in the EPO and Sham groups: (a) reduced hemorrhage in the EPO group (hematoxylin eosin-x40),
(b) histological appearance of the lung in the sham group(toluidine blue dye).
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hypovolemia, electrolytic changes, and fat emboli on
heart muscles [16-18]. In this study, no meaningful dif-
ference was observed in terms of troponin I values and
histopathological assessments among rat groups with
induced AP.
Acute renal failure is generally observed as a lethal
complication of AP [19-21]. In this study, only the cre-
atinine value of the kidney in the EPO group was found
to be significantly lower than that of the control group.
No changes were identified in terms of histopathology.
Among new treatment strategies, EPO therapy to retard
the course of neurodegenerative diseases and slow down
their damaging effects is considered promising [6,22,23].
Studies have already focused on the use of low molecular
weight heparin, dexamethasone, and octreotide for enceph-
alopathy developed in AP-induced rats [24,25]. However, asFigure 3 Distribution of mast cells in the groups: (a) Pronounced ede
group, (b) at larger magnification, the majority of mast cells are seen
EPO group (toluidine blue dye), (d) rare mast cells in the sham groupstudies have not yet focused on EPO use for brain damage
caused by induced AP, it is currently not possible to reach a
conclusion on this issue. In this study, no histopathological
changes were seen in the brain tissues of rats with induced
AP. However, further studies may produce more detailed
data on the inhibitive effect of EPO and secondary cerebral
damage caused by AP.
SIRS and MOF are the most frequent causes of mor-
tality in AP. Organ failures are considerably affected by
pulmonary complications. Three major pathological
mechanisms have been identified in ALI induced by
pancreatitis: (1) pulmonary endothelial dysfunction,
(2) leucocyte migration in interstitial area, and (3) distortion
of wall permeability and gas exchange due to morphological
pulmonary damage [10,26].
Pancreatitis-related ALI (PALI) is seen as one of the
causes of mortality in the initial days of the disease [10].ma and a multitude of mast cells in vascular proximity of control
to be degranulated, (c) decreased mast cell count and edema in
(toluidine blue dye).
Table 1 Evaluation of the histopathologic changes in
the lung
Lung injury score Groups [median (min-max)] p
Sham Control EPO*
Alveolar congestion 0 1 (0-1) 0 0,368
Hemorrhage 0 2 (1-2) 1 (0-1) 0,001
Alveolar septal infiltration 0 2 (1-2) 1 (1-1) 0,001
Alveolar wall thickness 0 2 (1-2) 1 (1-1) 0,001
Histopathological score: “0” normal, “1”mild, “2”moderate.
*Group EPO: Erythropoietin therapy group.
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minations, identified that 60% of patients had pulmonary
complications in the first week [27]. Johnson et al. identi-
fied pulmonary complications in 38–39% of patients [28].
Tascilar et al., by EPO (1000 U/kg, single dosage) therapy,
identified a meaningful reduction in alveolar edema and
polymorphonuclear cells (PMNL) in ALI induced by pan-
creatitis after 72 h [29]. Li et al., in the treatment of AP,
and Shang et al., in the treatment of lung injury caused by
lipopolysaccharide, applied a single dose of 3000 U/kg
EPO prior to the procedure. In both cases, positive histo-
pathological results were obtained. Meaningful reduction
in the lung tissue interstitial edema, hemorrhage, thicken-
ing of the alveolar wall, alveolar area, and inflammatory
cell infiltration were identified in the EPO group [30,31].
This result was correlated with the anti-inflammatory ef-
fect of EPO. Although this study did not show a meaning-
ful difference in terms of alveolar edema between the EPO
group and the other groups, a meaningful difference was
observed in neutrophils accumulated in alveolar septal cell
infiltration in the EPO group compared to the control
group. In contrast to our study, two cited studies have
applied EPO therapy with a single 1000 U/kg/day dose.
The EPO dosage is related to the cytoprotective inhib-
ition effect. Dosages provide systemic cytoprotection
at 100–1000 U/kg, neuroprotection at 350–5000 U/kg,
and cardioprotection at 3000–5000 U/kg [14,32].
In this study, a dosage of 1000 U/kg/day (third dose)
was used to reduce inflammatory cytokines and pro-
tect the cells from apoptosis. Alveolar edema deve-
loped secondary to pancreatitis is connected with the
increase in microvascular permeability [27]. It may be
considered that EPO protects endothelial cell integrity
and reduces lung damage [29]. The data show that EPO
administration can alleviate pulmonary injury parame-
ters in pancreatitis.
Mast cells are important due to their location around
blood capillaries and the lymphatic system and their ability
upon activation to cause allergic and inflammatory diseases
of the pulmonary system [10,12]. In ALI, the increase
in pulmonary neutrophil infiltration may be related to theextreme activity of macrophages and resulting chemotacti-
cal neutrophil migration, which cause the release of various
inflammatory mediators. In the ALI development process,
pancreatitis activates mast cells and then leukocytes, which
lead to endothelial wall dysfunction [10]. In a lung ischemia
reperfusion experiment in which rats were administered
mast cell stabilizer agent (cromolyn sodium) prior to the
procedure, a reduction in inflammatory response was iden-
tified [10,33]. In the histopathological assessment of this
study, the mast cell count of the EPO Group (9 ± 0.3) was
observed to be significantly lower than that of the control
group. The findings also support the therapeutic effect of
EPO in ALI treatment, similar to available literature data.
Conclusions
EPO is effective in limiting lung damage secondary to AP.
In this regard, it may be considered that it has positive
effects in the reduction of mast cell count in the lungs,
alveolar hemorrhage, septal neutrophil infiltration, and wall
thickness. However, further studies are required to investi-
gate the effects of EPO on the mast cells during ALI.
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